AngioDynamics Inc
NASDAQ:ANGO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
AngioDynamics Inc
Cost of Revenue
AngioDynamics Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
AngioDynamics Inc
NASDAQ:ANGO
|
Cost of Revenue
-$143.4m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
2%
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cost of Revenue
-$6.4B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-11%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cost of Revenue
-$1.4B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-8%
|
|
|
Stryker Corp
NYSE:SYK
|
Cost of Revenue
-$8.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-10%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cost of Revenue
-$19.6B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-8%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cost of Revenue
-$3.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
-16%
|
|
AngioDynamics Inc
Glance View
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacture, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The company is headquartered in Latham, New York and currently employs 800 full-time employees. The company went IPO on 2004-05-27. Its devices are used in minimally invasive, image-guided procedures. Its product offerings include Endovascular Therapies, Oncology/Surgery (OS) and Vascular Access (VA). Its Endovascular Therapies product offerings support the medical areas of Thrombus Management, Atherectomy, Peripheral Products (Core) and Venous Insufficiency. Its OS product offerings includes a range of ablation technologies, including thermal tissue ablation systems, surgical resection and the Irreversible Electroporation (IRE) technology, the NanoKnife System. Its portfolio of VA products includes peripherally inserted central catheters (PICCs), midline catheters, implantable ports, dialysis catheters and related accessories and supplies.
See Also
What is AngioDynamics Inc's Cost of Revenue?
Cost of Revenue
-143.4m
USD
Based on the financial report for Feb 28, 2026, AngioDynamics Inc's Cost of Revenue amounts to -143.4m USD.
What is AngioDynamics Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
2%
Over the last year, the Cost of Revenue growth was -11%. The average annual Cost of Revenue growth rates for AngioDynamics Inc have been 4% over the past three years , -2% over the past five years , and 2% over the past ten years .
